Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Advances in Treatment of Active, Moderate-To-Severe Graves’ Ophthalmopathy
source: The Lancet. Diabetes & Endocrinology
year: 2017
authors: Wiersinga WM
summary/abstract:Graves’ ophthalmopathy is defined as autoimmune inflammation of extraocular muscles and orbital fat or connective tissue, usually in patients with Graves’ disease. About one in 20 patients with Graves’ hyperthyroidism has moderate-to-severe Graves’ ophthalmopathy. Corticosteroids have been the mainstay of treatment, but new evidence about immune mechanisms has provided a basis to explore other drug classes. Intravenous methylprednisolone pulses are more effective and better tolerated than oral prednisone in the treatment of active, moderate-to-severe Graves’ ophthalmopathy. Rituximab has also been suggested as a possible replacement for intravenous corticosteroids.
Two randomised controlled trials of rituximab reached seemingly contradictory conclusions-rituximab was not better with respect to the primary outcome (clinical activity score) than placebo in one trial (which, however, was confounded by rather long Graves’ ophthalmopathy duration), but was slightly better than intravenous methylprednisolone pulses in the other (disease flare-ups occurred only in the latter group). On the basis of evidence published so far, rituximab cannot replace intravenous methylprednisolone pulses, but could have a role in corticosteroid-resistant cases.
Open-label studies of tumour-necrosis-factor-α blockade had limited efficacy, but other studies showed that interleukin-6 receptor antibodies were effective. Results of randomised controlled trials investigating the efficacy of the IGF-1 receptor antibody teprotumumab and the interleukin-6 receptor antibody tocilizumab are expected shortly. Approaches that target the causal mechanism of Graves’ ophthalmopathy (antibodies or antagonists that block thyroid-stimulating-hormone receptors) also look promising.
organization: University of Amsterdam, NetherlandsDOI: 10.1016/S2213-8587(16)30046-8
read more
myBinderRelated Content
-
“TED Today” Episode 5https://www.facebook.com/ThyroidEyes/vid...
-
Early Use of Steroid-Sparing Agents in the Inactivation of Moderate-to-Severe Active Thyroid eye DiseaseObjectives: The current first-line trea...
-
U.S. Physician Survey Illustrates the Devastating Impact of Thyroid Eye Disease on Patient Quality of LifeHorizon Therapeutics plc today announced...
-
Antithyroid Drugs (Beyond the Basics)Antithyroid drugs have several benefits ...
-
Risk Factors For Developing Thyroid-Associated Ophthalmopathy Among Individuals with Graves’ DiseaseImportance: Thyroid-associated ophthalm...
-
Graves’ Diseasehttps://medlineplus.gov/ency/images/ency...
-
Graves’ Orbitopathy as a Rare Disease in Europe: A European Group on Graves’ Orbitopathy (EUGOGO) Positi...Background: Graves' orbitopathy (GO) is...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Google